Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia
Vjollca Qerimi,1,2 Aleksandra Kapedanovska Nestorovska,1 Zoran Sterjev,1 Sonja Genadieva-Stavric,3 Ljubica Suturkova1 1Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, Macedonia; 2Institute of Public Health, Medical Decision Making and Health Technology Assessment, Departme...
Main Authors: | Qerimi V, Kapedanovska Nestorovska A, Sterjev Z, Genadieva-Stavric S, Suturkova L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-06-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/cost-effectiveness-analysis-of-treating-transplant-eligible-multiple-m-peer-reviewed-article-CEOR |
Similar Items
-
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialResearch in context
by: John R. Jones, et al.
Published: (2023-08-01) -
30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
by: Aurelia Chacon, et al.
Published: (2023-03-01) -
Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations
by: Amelie Boquoi, et al.
Published: (2022-04-01) -
Decision Tree C4.5 Performance Improvement using Synthetic Minority Oversampling Technique (SMOTE) and K-Nearest Neighbor for Debtor Eligibility Evaluation
by: Edi Priyanto, et al.
Published: (2023-08-01) -
Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study
by: Mads Harsløf, et al.
Published: (2024-04-01)